Nevirapine dose escalation for children may risk treatment failure

Full-dose nevirapine should be considered for HIV-positive children under two years of age in Africa, to simplify ART initiation and reduce the risk of suboptimal dosing, researchers reporting on a pharmacokinetic sub-study from the CHAPAS-1 trial argue in the advance online edition of AIDS .

http://www.aidsmap.com/Nevirapine-dose-escalation-for-children-may-risk-treatment-failure/page/2664742/